Thompson Investment Management Inc. Has $1.28 Million Stock Position in Abbott Laboratories $ABT

Key Points

• Thompson Investment Management increased its Abbott Laboratories position by 786% in the second quarter, bringing its holdings to 14,061 shares valued at approximately $1.28 million. Institutional investors collectively own 75.18% of ABT.
• Wall Street remains broadly optimistic, with an average “Moderate Buy” rating and an average price target of $118.67, despite several analysts recently lowering their targets.
• Abbott exceeded quarterly earnings and revenue estimates, reporting $1.31 in EPS and $12.59 billion in revenue, while projecting fiscal 2026 EPS of $5.45–$5.60. The company also declared a quarterly dividend of $0.63 per share, yielding about 2.3% annually.

Thompson Investment Management Inc. raised its position in Abbott Laboratories (NYSE:ABT - Free Report) by 786.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,061 shares of the healthcare product maker's stock after buying an additional 12,474 shares during the period. Thompson Investment Management Inc.'s holdings in Abbott Laboratories were worth $1,276,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ABT. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of several research analyst reports. Sanford C. Bernstein dropped their price objective on Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Robert W. Baird began coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target on the stock. Stifel Nicolaus cut their price target on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Daiwa Securities Group lowered Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price objective for the company. in a report on Wednesday, April 22nd. Finally, Oppenheimer lowered their price objective on Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $118.67.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wolfe Research upgraded Abbott Laboratories (ABT) from “peer perform” to “outperform” and set a $130 target, implying substantial upside from recent trading levels. Benzinga analyst upgrade report
• Positive Sentiment: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market growth, broad branded-generic offerings and resilient healthcare demand. Expanding biosimilar opportunities could provide an additional long-term growth avenue. Zacks EPD growth report
• Positive Sentiment: Abbott and Google Health announced a multiyear partnership to integrate Abbott’s Lingo continuous glucose-monitoring data into Google’s AI-powered consumer health tools. The collaboration could increase Lingo’s visibility, support personalized metabolic-health services and generate valuable real-world data. Abbott and Google Health Lingo partnership
• Positive Sentiment: Bank of America Securities issued a “buy” recommendation for ABT, reinforcing the constructive Wall Street view. Bank of America buy rating
• Neutral Sentiment: Abbott’s stock outperformed competitors during a strong broader trading session, reflecting market momentum but not a new company-specific fundamental catalyst. MarketWatch trading report
• Neutral Sentiment: Abbott’s PULSE study is evaluating earlier treatment for atrial fibrillation. Positive clinical results could expand future device demand, but the study remains ongoing and carries execution and clinical risk. TipRanks PULSE study report
• Neutral Sentiment: Abbott renewed its blood-donation campaign with the Big Ten amid a U.S. blood shortage. The initiative supports Abbott’s brand and blood-management business, though its direct near-term financial impact is likely limited. Abbott and Big Ten blood donation campaign

Abbott Laboratories Stock Up 0.4%

Shares of NYSE ABT opened at $111.37 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a market cap of $192.71 billion, a P/E ratio of 36.04, a P/E/G ratio of 2.15 and a beta of 0.59. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The business has a 50-day simple moving average of $97.27 and a two-hundred day simple moving average of $99.75.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories's payout ratio is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source